MMR-deficient cancers are now acknowledged to be sensitive to anti-PD1 (nivolumab, pembrolizumab) with or without anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies [89,90]. This evidence concerns the gene CTLA4 and cancer.